BioMarin Acquires Amicus for $4.8B, Shares Surge

BioMarin Pharmaceuticals shares surged by nineteen percent after announcing an all-cash acquisition of Amicus Therapeutics for approximately four billion dollars. The deal, valued at fourteen dollars and fifty cents per share, represents a thirty-three percent premium over Amicuss last closing price. The acquisition will add two treatments to BioMarins product lineup, potentially boosting revenue growth and earnings per share. Both companies boards have approved the merger, and BioMarins shares closed the day at sixty-one dollars and nineteen cents, marking a seventeen point eight percent increase. This acquisition could significantly reshape BioMarins future growth trajectory in the rare disease market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.